Diurnal variation of connective tissue metabolites in early and long-standing rheumatoid arthritis and in healthy individuals

References

• Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 2000;43:953–68.
   PubMed Web of Science ®Google Scholar
• Horslev-Petersen K, Bentsen KD, Halberg P, Junker P, Kivirikko KI, Majamaa K, Connective tissue metabolites in serum as markers of disease activity in patients with rheumatoid arthritis. Clin Exp Rheumatol 1988;6:129–34.
   PubMed Web of Science ®Google Scholar
• Horslev-Petersen K, Kim KY, Pedersen LR, Bentsen KD, Uldbjerg N, Oxlund H, Serum aminoterminal type III procollagen peptide. Relation to biosynthesis of collagen type III in experimentally induced granulation tissue in rats. APMIS 1988; 96:793–804.
   Google Scholar
• Horslev-Petersen K, Bentsen KD, Junker P, Mathiesen FK, Hansen TM, Lorenzen I. Serum aminoterminal type III procollagen peptide in inflammatory and degenerative rheumatic disorders. Clin Rheumatol 1988;7:61–8.
   PubMed Web of Science ®Google Scholar
• Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:21–30.
   PubMedGoogle Scholar
• Garnero P, Geusens P, Landewe R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S54–8.
   PubMedGoogle Scholar
• Jensen LT, Henriksen JH, Olesen HP, Risteli J, Lorenzen I. Lymphatic clearance of synovial fluid in conscious pigs: the aminoterminal propeptide of type III procollagen. Eur J Clin Invest 1993;23:778–84.
   PubMedGoogle Scholar
• Engstrom-Laurent A, Hallgren R. Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients. Relationship to synovitis mass and morning stiffness. Arthritis Rheum 1987;30:1333–8.
   PubMed Web of Science ®Google Scholar
• Manicourt DH, Poilvache P, Nzeusseu A, van Egeren A, Devogelaer JP, Lenz ME, Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest. Arthritis Rheum 1999;42:1861–9.
   PubMedGoogle Scholar
• Andersson ML, Petersson IF, Karlsson KE, Jonsson EN, Mansson B, Heinegard D, Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis. Ann Rheum Dis 2006;65:1490–4.
   PubMed Web of Science ®Google Scholar
• Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209–15.
   PubMed Web of Science ®Google Scholar
• Wolthers OD, Heuck C, Heickendorff L. Diurnal variations in serum and urine markers of type I and type III collagen turnover in children. Clin Chem 2001;47:1721–2.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• van Riel PL, Scott DL, van Gestel AM. EULAR handbook of clinical assessments in rheumatoid arthritis, 1st edn. The Netherlands, Van Zuiden Communications B.V., 2000.
   Google Scholar
• Thorsen H, Hansen TM, McKenna SP, Sorensen SF, Whalley D. Adaptation into Danish of the Stanford Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life Scale (RAQoL). Scand J Rheumatol 2001;30:103–9.
   PubMed Web of Science ®Google Scholar
• Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992;31:583–91.
   PubMedGoogle Scholar
• Laurent TC, Fraser JR. Hyaluronan. FASEB J 1992;6:2397–404.
   PubMed Web of Science ®Google Scholar
• Neidhart M, Hauser N, Paulsson M, DiCesare PE, Michel BA, Hauselmann HJ. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 1997;36:1151–60.
   PubMedGoogle Scholar
• Jordan JM, Luta G, Stabler T, Renner JB, Dragomir AD, Vilim V, Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum 2003;48:675–81.
   PubMed Web of Science ®Google Scholar
• Andersson M, Thorstensson C, Roos E, Petersson IF, Heinegard D, Saxne T. Serum-COMP levels increase during physical exercise in patients with knee osteoarthritis. Osteoarthritis Cartilage 2003;11 (Suppl A):10.
   Google Scholar
• Mundermann A, Dyrby CO, Andriacchi TP, King KB. Serum concentration of cartilage oligomeric matrix protein (COMP) is sensitive to physiological cyclic loading in healthy adults. Osteoarthritis Cartilage 2005;13:34–8.
   PubMed Web of Science ®Google Scholar
• Neidhart M, Müllers-Ladner U, Frey W, Bosserhoff AK, Colombani PC, Frey-Rindova P, Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis Cartilage 2000;8:222–9.
   PubMed Web of Science ®Google Scholar